Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 1968-1976

  Takata, Takanobu ^a   Ishigaki, Yasuhito ^a   Shimasaki, Takeo ^a   Tsuchida, Hideyuki ^a   Motoo, Yoshiharu ^a   Hayashi, Akio ^b   Tomosugi, Naohisa ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b YOKOGAWA ANALYTICAL SYSTEMS INC   (Japan)

Author keywords

14 3 3 Protein sigma; Gemcitabin; Lactoferrin; PANC 1; Secretome

Indexed keywords

CALGRANULIN A; CALGRANULIN B; GALECTIN 7; GEMCITABINE; LACTOFERRIN; NUCLEIC ACID PRECURSOR; STRATIFIN; TRANSFERRIN; VITAMIN D BINDING PROTEIN;

CANCER CELL; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEIN SECRETION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; LACTOFERRIN; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEOMICS; S100 PROTEINS; TRANSFERRIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84868156091     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2020     Document Type: Conference Paper

References (52)

1. Haugk B: Pancreatic intraepithelial neoplasia - can we detect early pancreatic cancer? Histopahology 57:503-514, 2010.
2. Tanaka M, Javel M, Dong X and Eng C, Abbruzzese JL and Li D: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116:5325-5335, 2010.
3. Shimasaki T, Ishigaki Y, Minamoto T and Motoo R: The influence of expression of Apopthosis related genes in pancreatic cell lines treated with gemcitabine hydrochrolide. Suizo 22:14-20, 2007.
4. Wallentine JC, Kim KK, Seiler CE III, Vaughn CP, Crockett DK, Tripp SR, Elenitoba-Johnson KS and Lim MS: Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest 87:1113-1124, 2007. (Pubitemid 47609024)
5. Xue H, Lu B and Lai M: The cancer secretome: a reservoir of biomarkers. J Trans Med 6:1-12, 2008.
6. Soares J C S, Santos MF, Trrugilho M R O, Neves-Ferreira A G G, Perales J and Domont GB: Differential proteomics of the plasma of individuals with sepsis caused by Acinetobacter bumannii. J Proteomics 73:267-278, 2009.
7. Mares J, Thongboonkerd V, Tuma Z, Moravec J, Karvunidis T and Matejovic M: Proteomic analysis of proteins bound to adsorption units of extracorporeal liver support system under clinical conditions. J Proteome Res 8:1756-1764, 2008.
8. Sun Q, Sha H, Yang X, Bao G, Lu J and Xie Y: Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol 137:521-532, 2010.
9. Shi J, Zen Y and Zheng R: Proteome profiling of early seed development in Cunninghamia lanceolata (Lamb.) Hook. J Exp Bot 61:2367-2381, 2010.
10. Oshita F, Morita A, Ito H, Kameda Y, Tsuchiya E, Shigeru A and Miyagi Y: Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer. Oncol Rep 24:637-645, 2010.
11. Varo I, Rigos G, Navarro JC, Del Ramo J, Giner C, Hernandez A, Pertusa J and Torreblanca A: Effect of ivermectin on the liver of gilthead sea bream Sparus aurata: a proteomic approach. Chemosphere 80:570-577, 2010.
12. Schagger H and Von Jagow W: Tricine-sodium dodecyl sulfatepolyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166:368-379, 1987. (Pubitemid 18004907)
13. Chillini C, Cochet O, Negroni L, Samson M, Poggi M, Ailhaud G, Alessi MC, Dani C and Amri EZ: Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol 9:1-16, 2008.
14. Hathout Y: Approaches to the study of the cell secretome. Expert Rev Proteomics 4:239-248, 2007. (Pubitemid 46588459)
15. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5:157-171, 2006. (Pubitemid 43169348)
16. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenbrg DA, Reddy RC, Akulapalli S, Thannickal VJ, et al: Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 5:1143-1154, 2006. (Pubitemid 43727792)
17. Yamashita R, Fujikawa Y, Ikari K, Hamada K, Otomo A, Yasuda K, Noda M and Kaburagi Y: Extracellular proteome of human hepatoma cell, HepG2 analyzed using two-dimensional liquid chromatography coupled with tandem mass spectrometry. Mol Cell Biochem 298:83-92, 2007. (Pubitemid 46605286)
18. Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY, Yu CJ, Tang R, Hsieh LL, Yu JS and Chang YS: Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8:316-332, 2007. (Pubitemid 351212330)
19. Ma Y, Visser L, Roelofsen H, De Vries M, Diepstra A, Van Imhoff G, Van Der Wal T, Luinge M, Alvarez-Llamas G, Vos H, et al: Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 111:2339-2346, 2008. (Pubitemid 351451442)
20. Butler GS, Dean RA, Etam EM and Overall CM: Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol 28:4896-4914, 2008.
21. Sarkissian G, Ferglot P, Lamy PJ, Petard JJ, Culine S, Jouin P, Rioux-Leclercq N and Darbouret B: Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 54:574-581, 2008. (Pubitemid 351348152)
22. Tunica DG, Yin X, Sidibe A, Stegemann C, Nissum M, Zeng L, Brunet M and May M: Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/MS. Proteomics 9:4991-4996, 2009.
23. Mohammad DH and Yaffe MB: 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair 8:1009-1017, 2009.
24. Morrison DK: The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trens Cell Biol 19:16-23, 2009.
25. Obsilova V, Sihan J, Boura E, Teisinger J and Obsil T: 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 57(Suppl 3):S11-S21, 2008.
26. Ferl RJ, Manak MS and Reyes MF: The 14-3-3 σ reviews. Genome Biol 3:30101-30107, 2002.
27. Yang H, Wen Y, Chen C, Loxano G and Lee M: 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 23:7096-7107, 2003. (Pubitemid 37210993)
28. Lambiase A, Micera A, Pellegrini G, Merlo D, Rama P, Luca MD and Bonini S: In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci 50:4622-4630, 2009.
29. Hermerking H: Extracellular 14-3-3 sigma protein: a potential mediator of epithelial-mesenchymal interactions. J Invest Dermatol 124:9-10, 2005.
30. Ghahary A, Marcoux Y, Karimi-Busheri F, Li Y, Tredget EE, Kilani RT, Lam E and Weinfeld M: Differentiated keratinocyte-releasable stratifin (14-3-3 sigma) stimulates MMP-1 expression in dermal fibroblasts. J Invest Derrmatol 122:1188-1197, 2004.
31. Steijns JM and Van Hooijdonk AC: Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr 84:11-17, 2000.
32. Masson PL, Heremans JF and Dire CH: Lactoferrin, an ironbinding protein in neutrophilic leukocytes. Clin Chim Acta 14:735-739, 1996.
33. De Vet B J C M and Van Gool J: Lactoferrin and iron absorption in the small intestine. Acta Med Scand 196:393-402, 1974.
34. Mason DY and Taylor CR: Distribution of transferrin, ferritin and lactotranseferrin human tissues. J Clin Pathol 31:316-327, 1978. (Pubitemid 8315980)
35. Brock J: Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child 55:417-421, 1980.
36. Reitamo S, Konttinen YT and Segerberg-Konttinen M: Distribution of lactoferrin in human salivary glands. Histochemistry 66:285-291, 1980. (Pubitemid 10057401)
37. Korsud FR and Brandtzaeg P: Characterization of epithelial elements in human major salivary gland by functional markers: localization of amylase, lactoferrin, lysozyme, secretory component, and secretory immunoglobulins by paired immunofluorescence staining. J Histochem Cytochem 30:657-666, 1982. (Pubitemid 13224408)
38. Caselitz J, Jaup T and Seifert G: Lactoferrin and lysozyme in carcinomas of the parotid gland. A comparative immunocytochemical study with the occurrence in normal and inflamed tissue. Virchows Arch A Pathol Anat Histol 394:61-73, 1981. (Pubitemid 12249238)
39. Barresi G and Tuccari G: Lactoferrin in benign hypertrophy and carcinomas of the prostatic gland. Virchows Arch A Pathol Anat Histopathol 403:59-66, 1984. (Pubitemid 14103985)
40. Rossiello R, Carriero MV and Giordano GG: Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol 37:51-55, 1984. (Pubitemid 14218063)
41. Charpin C, Lachard A, Pourreau SN, Jacquemier J, Lvaut MN, Andonian C, Martin PM and Toga M: Localization of lactoferrin and nonspecifc cross-reacting antigen in human breast carcinomas. An immunohistochemical study using the avidin-biotin-peroxidase complex method. Cancer 55:2612-2617, 1984. (Pubitemid 15092146)
42. Tuccari G and Barresi G: Immunohistochemical demonstration of lactoferrin in follicular adenomas and thyroid carcinomas. Virchows Arch A Pathol Anat Histopathol 406:67-74, 1985. (Pubitemid 15083762)
43. Baressi G and Tuccari G: Iron-binding proteins in thyroid tumours. An immunocytochemical study. Pathol Res Pract 182:344-351, 1987. (Pubitemid 17111039)
44. Louglin KR, Gittes RF and Patridge D: The relationship of lactoferrin to the anemia of renal carcinoma. Cancer 59:566-571, 1987. (Pubitemid 17002440)
45. Tuccari G, Barresi G, Arena F and Inferrera C: Immunocytochemical detection of lactoferrin in human gastric carcinomas and adenomas. Arch Pathol Lab Med 113:912-916, 1989.
46. Carbaret V, Vilain MO, Delobelle-Deroide A and Vanseymortier L: Immunohistochemical demonstration of ceruloplasmin and lactoferrin in a series of 59 thyroid tumors. Ann Pathol 12:347-352, 1992 (In French). (Pubitemid 23079917)
47. Tuccari G, Rizzo A, Crisafulli C and Barresi G: Iron-binding proteins in human colorectal adenomas and carcinomas: an immunocytochemical investigation. Histol Histopathol 7:543-547, 1992.
48. Yossie Asato De Camargo R, Longatto Filho A, Alves VA, Bisi H, Kanamura CT and Alves Abelin NM: Lactoferrin in thyroid lesions: immunoreactivity in fine needle aspiration biopsy samples. Acta Cytol 40:408-413, 1996. (Pubitemid 26189667)
49. Tuccari G, Rossiello R and Barresi G: Iron binding proteins in gallbladder carcinomas. An immunocytochemical investigation. Histol Histopathol 12:671-676, 1997. (Pubitemid 27314698)
50. Tucarri G, Giffre G, Crisafulli C and Barresi G: Immnohistochemical detection of lactoferrin in human astrocytomas and multiforme glioblastomas. Eur J Histochem 43:317-322, 1999. (Pubitemid 30052189)
51. Bezault J, Bhimani R, Wiprovnick J and Fumanski P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 54:2310-2312, 1994. (Pubitemid 24138715)
52. Sakamoto N: Antitumor effect of human lactoferrin against newly established human pancreatic cancer cell line SPA. Gan To Kagaku Ryoho 25:1557-1563, 1998 (In Japanese).